Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery.

Published

Journal Article

OBJECTIVE: Oral P2Y₁₂ platelet receptor inhibitors are a cornerstone of reducing complications in patients with acute coronary syndromes or coronary stents. Guidelines advocate discontinuing treatment with P2Y₁₂ platelet receptor inhibitors before surgery. Cangrelor, a short-acting, reversible, intravenously administered P2Y₁₂ platelet inhibitor is effective in achieving appropriate platelet inhibition in patients who are awaiting coronary artery bypass grafting (CABG) and require P2Y₁₂ inhibition. The objective of this study was to assess the effects of preoperative cangrelor on the incidence of perioperative complications, which are currently unknown. METHODS: Patients (n = 210) requiring preoperative clinical administration of thienopyridine therapy were randomized in a multicenter, double-blinded study to receive cangrelor or placebo while awaiting CABG after discontinuation of the thienopyridine. Optimal platelet reactivity, which was defined as <240 P2Y₁₂ platelet reaction units, was measured with serial point-of-care testing (VerifyNow). Pre- and postoperative outcomes, bleeding values, and transfusion rates were compared. To quantify potential risk factors for bleeding, we developed a multivariate logistic model. RESULTS: The differences between the groups in bleeding and perioperative transfusion rates were not significantly different. The rate of CABG-related bleeding was 11.8% (12/102) in cangrelor-treated patients and 10.4% (10/96) in the placebo group (P = .763). Transfusion rates for the groups were similar. Serious postoperative adverse events for the cangrelor and placebo groups were 7.8% (8/102) and 5.2% (5/96), respectively (P = .454). CONCLUSIONS: Compared with placebo, bridging patients with cangrelor prior to CABG effectively maintains platelet inhibition without increasing post-CABG complications, including bleeding and the need for transfusions. These data suggest cangrelor treatment is a potential strategy for bridging patients requiring P2Y₁₂ receptor inhibition while they await surgery.

Full Text

Duke Authors

Cited Authors

  • Firstenberg, MS; Dyke, CM; Angiolillo, DJ; Ramaiahm, C; Price, M; Brtko, M; Welsby, I; Chandna, H; Holmes, DR; Voeltz, M; Tummala, P; Hutyra, M; Manoukian, SV; Prats, J; Todd, M; Liu, T; Chronos, N; Dietrich, M; Montalescot, G; Cannon, LA; Topo, EJ

Published Date

  • April 2013

Published In

Volume / Issue

  • 16 / 2

Start / End Page

  • E60 - E69

PubMed ID

  • 23625478

Pubmed Central ID

  • 23625478

Electronic International Standard Serial Number (EISSN)

  • 1522-6662

Digital Object Identifier (DOI)

  • 10.1532/HSF98.20121103

Language

  • eng

Conference Location

  • United States